Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

Saved in:
Bibliographic Details
Title: Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.
Authors: Stern S; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Zhang Y; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Pressly M; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Yang X; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Abdel-Rahman S; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Wang J; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Chen MC; School of Pharmacy, College of Pharmacy, Taipei Medical University, 250 Wuxing St., Taipei 110301, Taiwan., Chen CH; Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing St., Taipei 110301, Taiwan., Pepe S; Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Doi M; Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Burckart GJ; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Yao LP; Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Schuck R; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA., Bai JP; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA. Electronic address: Jane.Bai@fda.hhs.gov.
Source: Journal of pharmaceutical sciences [J Pharm Sci] 2026 Jun 20; Vol. 115 (9), pp. 104401. Date of Electronic Publication: 2026 Jun 20.
Publication Type: Journal Article; Review
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6017 (Electronic) Linking ISSN: 00223549 NLM ISO Abbreviation: J Pharm Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1520-6017
DOI:10.1016/j.xphs.2026.104401